Proceedings on Cancer-Immuno-Oncology

Immunogenicity / Biomarker

Human leukocyte antigens and haplotypes allow for prognostic classification of HNSCC patients

Gunnar Wichmann, Andreas Dietz, Susanne Wiegand

Immunogenicity / Biomarker, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810001 • DOI: 10.18416/CIO.2018.1810001
Breaking the brake: targeting the immunosuppressive cells to optimize immunotherapy of cancer

Marco C. Merlano, Andrea Abbona, Ornella Garrone

Immunogenicity / Biomarker, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810002 • DOI: 10.18416/CIO.2018.1810002
Immunotherapy and head and neck cancer: Focus on recurrent and metastatic disease

Robert Haddad

Immunogenicity / Biomarker, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810004 • DOI: 10.18416/CIO.2018.1810004

Liquid Biopsy

Extracellular Vesicles as biomarkers for cancer progression and cancer associated VTE

Frank Gieseler, Fanny Ender

Liquid Biopsy, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810005 • DOI: 10.18416/CIO.2018.1810005
Immune modulation by extracellular vesicles released from mesenchymal cells

Martina Seifert

Liquid Biopsy, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810006 • DOI: 10.18416/CIO.2018.1810006

Cellular Vaccines

CAR NK cells for cancer retargeting

Ruth Esser, Ulrike Koehl, Wolfgang Glienke, Michael Morgan, Andrew Kaiser, Hinrich Abken, Michael Heuser, Krasimira Aleksandrova, Jana Leise, Olaf Oberschmidt, Christoph Priesner, Lubomir Arseniev, Axel Schambach, Stephan Kloess

Cellular Vaccines, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810009 • DOI: 10.18416/CIO.2018.1810009
Immune biological rationale for the design of radioimmunotherapies

Udo S. Gaipl

Cellular Vaccines, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810010 • DOI: 10.18416/CIO.2018.1810010
Role of resident memory T cells in cancer immunotherapy

Eric Tartour

Cellular Vaccines, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810011 • DOI: 10.18416/CIO.2018.1810011
Perspectives of human gamma/delta T-cells in cancer immunotherapy

Dieter Kabelitz

Cellular Vaccines, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810012 • DOI: 10.18416/CIO.2018.1810012

New Targets

On the development of personalized cancer vaccines

Hans-Georg Rammensee

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810013 • DOI: 10.18416/CIO.2018.1810013
Platelets regulate innate immunity in autoinflammatory diseases and cancer

Bernardo Simoes Franklin

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810014 • DOI: 10.18416/CIO.2018.1810014
A pan-cancer landscape of interactions between tumors and infiltrating immune cells

David Tamborero

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810015 • DOI: 10.18416/CIO.2018.1810015
Rediscovering an old story: HLA class I alterations and immune escape of tumors in the context of immunotherapies

Barbara Seliger

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810029 • DOI: 10.18416/CIO.2018.1810029
Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells

Kerstin Schütze, Julia Hambach, Katharina Petry, William Fumey, Birte Albrecht, Levin Schriewer, Jana Röckendorf, Stephan Menzel, Friedrich Haag, Catelijne Stortelers, Peter Bannas, Friedrich Koch-Nolte

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810041 • DOI: 10.18416/CIO.2018.1810041
Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells

Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. König, Stefan Endres, Caroline C. Friedel, Max Schnurr, Peter Duewell

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810042 • DOI: 10.18416/CIO.2018.1810042
Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines

Paulina Vogt, Frank Köster, Stephan Polack, Achim Rody, Karen Bräutigam

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810043 • DOI: 10.18416/CIO.2018.1810043
Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7

Elodie Kabore, Frank Köster, Stephan Polack, Achim Rody, Karen Bräutigam

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810044 • DOI: 10.18416/CIO.2018.1810044
Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies

Vera Bauer, Fatima Ahmetlic, Tanja Riedel, Nico Trautwein, Tim Sparwasser, Stefan Stevanovic, Martin Röcken, Ralph Mocikat

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810045 • DOI: 10.18416/CIO.2018.1810045
Specific targeting of oncogenic mutations using CRISPR-technology to destroy activated oncogenes and enhance immune response

Felix Oppel, Matthias Schürmann, Holger Sudhoff

New Targets, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810046 • DOI: 10.18416/CIO.2018.1810046

Microbiome

Tumor and host factors regulating anti-tumor immunity and immotherapy efficacy

Thomas F. Gajewski

Microbiome, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810019 • DOI: 10.18416/CIO.2018.1810019

Resistance / Immunosuppression

MDSC as a new target for cancer immunotherapy

Viktor Umansky

Resistance / Immunosuppression, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810022 • DOI: 10.18416/CIO.2018.1810022
Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy

Christian Blank

Resistance / Immunosuppression, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810023 • DOI: 10.18416/CIO.2018.1810023
Interference between tumor mutational burden, HPV status, immune signatures and outcome in patients with head and neck cancer treated with chemoradiotherapy: Results from a multicenter retrospective study of the German Cancer Consortium Radiation Oncology

I. Tinhofer, T. Eder, A. K. Hess, V. Fleischer, P. Balermpas, C. Rödel, A. Linge, M. Krause, M. Baumann, M. Stuschke, D. Zips, A. L. Grosu, A. Abdollahi, J. Debus, U. Ganswindt, C. Belka, S. Pigorsch, G. Multhoff, S. E. Combs, V. Budach

Resistance / Immunosuppression, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810024 • DOI: 10.18416/CIO.2018.1810024

Combinational Strategies

Dynamics of conversation: Immunotherapy meets tumor microenvironment

Iris Helfrich

Combinational Strategies, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810025 • DOI: 10.18416/CIO.2018.1810025
Modulating the tumor microenvironment

Dirk Jäger

Combinational Strategies, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810027 • DOI: 10.18416/CIO.2018.1810027

Immunomodulation / Tumor Biology

Integrin ?4 synergizes with E-and P-selectin to regulate tumor growth: Unravelling the molecular mechanisms

Sandra Hanika, Vera Labitzky, Florian Gebauer, Daniel Wicklein, Hanna Maar, Tobias Gosau, Jennifer Schröder-Schwarz, Stefan Linder, Kristoffer Riecken, Udo Schumacher, Tobias Lange

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810033 • DOI: 10.18416/CIO.2018.1810033
Primary and recurrent head and neck squamous carcinomas are strikingly different regarding their immune microenvironment

Christian Watermann, Helen Pasternack, Christian Idel, Sven Perner, Rosemarie Krupar, Julika Ribbat-Idel, Mark Philipp Kühnel, Danny Jonigk, Johannes Brägelmann

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810035 • DOI: 10.18416/CIO.2018.1810035
The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer

Lisanne Heim, Juliane Friedrich, Marina Engelhardt, Denis I. Trufa, Carol I. Geppert, Ralf J. Rieker, Horia Sirbu, Susetta Finotto

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810036 • DOI: 10.18416/CIO.2018.1810036
Role of glycolysis for intestinal inflammation and carcinogenesis

Jacob Hamm, Kenneth Klischies, Nina Sommer, Philip Rosenstiel, Felix Sommer

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810037 • DOI: 10.18416/CIO.2018.1810037
MALDI-imaging: Identification of protein signatures of genomic instability in colorectal cancers

Timo Gemoll, Oliver Klein, Elena Miroll, Christoph Thorns, Jens Habermann

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810039 • DOI: 10.18416/CIO.2018.1810039
Investigating a potential role of Got1 in T cell exhaustion.

Nina Weisshaar

Immunomodulation / Tumor Biology, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810040 • DOI: 10.18416/CIO.2018.1810040

Therapy Prognosis / Prediction

Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma

Chao Rong, Bohai Feng, Marie Muller, Dana Holzinger, Christa Flechtenmacher, Julia Thierauf, Annette Affolter, Peter Plinkert, Jochen Hess

Therapy Prognosis / Prediction, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810047 • DOI: 10.18416/CIO.2018.1810047
The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis

Fanny Ender, Melanie Klee, Mario Kramer, Axel Merseburger, Ralph Pries, Gabriela Riemekasten, Achim Rody, Barbara Wollenberg, Frank Gieseler

Therapy Prognosis / Prediction, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810048 • DOI: 10.18416/CIO.2018.1810048
CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer

Holger Sudhoff, Liam Masterson, Piyush Jani, Jane Carolyn Sterling, Peter Goon

Therapy Prognosis / Prediction, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810050 • DOI: 10.18416/CIO.2018.1810050

Therapeutic Strategies / Approaches

Current status of radiotherapy/radiochemotherapy and immunotherapy combinations– a German survey

Lukas Käsmann, Chukwuka Eze, Olarn Roengvoraphoj, Claus Belka, Farkhad Manapov

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810051 • DOI: 10.18416/CIO.2018.1810051
Activation of immune response in refractory patients to standard treatment (T.R.A.N.S.L.A.T.E.)

Andrea Abbona, Dario Sangiolo, Marco Merlano, Ornella Garrone, Merlotti Anna, Martino Monteverde, Cristiana Lo Nigro, Antonella Falletta, Marcella Occelli, Chiara Varamo, Massimo Aglietta, Loretta Gammaitoni, Alessia Reali

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810052 • DOI: 10.18416/CIO.2018.1810052
Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies?

Yannic Bartsch, Marc Ehlers

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810053 • DOI: 10.18416/CIO.2018.1810053
Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo

Eric Freund, Ramona Clemen, Rajesh Kumar Gandhirajan, Sander Bekeschus

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810055 • DOI: 10.18416/CIO.2018.1810055
Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma

Julia Schröder, Stefan Rödiger, Madeleine Ruhe, P. Markus Deckert

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810056 • DOI: 10.18416/CIO.2018.1810056
Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas

Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Büttner, Jürgen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt, Roland T. Ullrich

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810057 • DOI: 10.18416/CIO.2018.1810057
Robust GMP manufacturing process with IL-2 and a glycoprotein antibody cocktail generates highly active human NK cell batches for cancer immunotherapy

Katharina Bröker, Udo Schumacher, Ralf Pörtner, Hans Hoffmeister, Evgeny Sinelnikov, Stefan Lüth, Werner Dammermann

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810058 • DOI: 10.18416/CIO.2018.1810058
Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils

Anna-Sophie Decker, Ekaterina Pylaeva, Alexandra Brenzel, Sharareh Bordbari, Ilona Spyra, Stephan Lang, Jadwiga Jablonska

Therapeutic Strategies / Approaches, Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810059 • DOI: 10.18416/CIO.2018.1810059